BEX3

BEX3 (NADE) is an intrinsically disordered, higher-order oligomeric adaptor protein that couples neurotrophin receptor signaling to apoptotic and transcriptional outputs (PMID:10764727, PMID:26383250). It was first defined as a p75NTR death-domain binding partner whose co-expression drives NGF-dependent caspase-2/3 activation and DNA fragmentation, with an apoptosis-executing core in residues 41–71 and a C-terminal regulatory region (72–112) governing NGF dependence (PMID:10764727, PMID:11830582). A leucine-rich nuclear export signal (residues 90–100) is required for nuclear export, self-association, and p75NTR binding, and biophysical analysis maps a proteolysis-resistant globular core to residues ~55–120 flanked by partially folded termini (PMID:11830582, PMID:26383250). BEX3 also acts in the nucleus as a transcriptional regulator: dimerization-dependent shuttling allows it to associate with a region immediately upstream of the trkA transcription start site and enhance basal and NGF-induced TrkA expression, promoting neuronal survival and differentiation (PMID:25948268). Its abundance is controlled by the proteasome, and the TSC1 product hamartin constitutively binds BEX3 to prevent its degradation, a stabilization required for NGF-induced apoptosis (PMID:17355907). BEX3 further engages Smac/DIABLO to block XIAP-mediated Smac ubiquitination and promote TRAIL-induced apoptosis, and antagonizes DRG-1-driven proliferation (PMID:15178455, PMID:16777077). In vivo, two murine Bex3 alleles produce reduced interneuron number and hippocampal circuit imbalance, establishing a requirement for normal brain function (PMID:33100228).

1. 2000 High

   Established BEX3/NADE as a death-domain effector that links p75NTR to the apoptotic machinery, answering how the receptor triggers cell death.

   Evidence Yeast two-hybrid against p75NTR plus co-expression apoptosis assays in 293T, PC12, nnr5 and oligodendrocytes

   PMID:10764727

   Open questions at the time

   • Did not define the structural basis or the BEX3 residues mediating the interaction
   • Downstream of caspase activation left unresolved
2. 2002 High

   Mapped the functional architecture of BEX3, showing distinct apoptosis-executing and regulatory regions and that a leucine-rich NES couples export, self-association, and p75NTR binding to apoptosis.

   Evidence Truncation/point mutagenesis with nuclear export, co-IP, and apoptosis readouts in oligodendrocytes

   PMID:11830582

   Open questions at the time

   • Mechanism by which export and oligomerization are mechanistically coupled not resolved
   • No structural model of the active region
3. 2003 Medium

   Identified dynactin as a BEX3 partner and revealed species/context dependence of p75NTR coupling, while showing forced expression suppresses tumor growth in vivo.

   Evidence Yeast two-hybrid, co-IP, and stable transfection xenograft growth assays (CHO, MDA-MB-231)

   PMID:12739005

   Open questions at the time

   • Negative p75NTR co-IP conflicts with earlier interaction data; cause unresolved
   • Mechanism of tumor suppression not defined
   • Functional relevance of dynactin binding untested
4. 2004 Medium

   Connected BEX3 to additional pathways by demonstrating Smac/DIABLO binding that inhibits XIAP-mediated Smac ubiquitination and promotes TRAIL-induced apoptosis, and an OMP interaction able to relocalize OMP.

   Evidence Yeast two-hybrid/pulldown, domain mapping, co-IP, ubiquitination and apoptosis assays (MCF-7); phage display and chemical cross-linking for OMP

   PMID:12911636 PMID:15178455 PMID:15198671

   Open questions at the time

   • Single-lab interaction data without reciprocal in vivo validation
   • Physiological context of OMP interaction not established
5. 2004 Medium

   Localized BEX3 to perinuclear mitochondria undergoing DNA replication and defined sequence requirements (NES and CaaX box) for this targeting, linking it to cell growth.

   Evidence GFP-fusion deconvolution microscopy, NES/CaaX deletion mutagenesis, siRNA knockdown growth assay in F9 cells

   PMID:15563833

   Open questions at the time

   • Functional role of mitochondrial localization not defined
   • Single cell line
6. 2005 Low

   Distinguished BEX3 from paralogs by its cytoplasmic localization and proteasomal turnover, and predicted a metal-binding histidine-rich domain.

   Evidence Subcellular fractionation/microscopy, proteasome inhibitor treatment, sequence analysis of rat Bex proteins

   PMID:15958283

   Open questions at the time

   • Metal binding predicted from sequence only, no direct binding assay
   • Single study
7. 2006 Medium

   Implicated BEX3 in negative control of proliferation by showing it antagonizes DRG-1-driven cell-cycle progression.

   Evidence Yeast two-hybrid, co-IP with domain mapping, MTT proliferation and flow cytometry cell-cycle analysis

   PMID:16777077

   Open questions at the time

   • Molecular mechanism of cell-cycle antagonism unresolved
   • Single lab
8. 2007 High

   Identified hamartin (TSC1) as a constitutive BEX3 partner that protects it from proteasomal degradation, defining the upstream control of BEX3 abundance needed for apoptosis.

   Evidence Yeast two-hybrid, coiled-coil pulldown, co-IP, immunofluorescence in neurons/mouse brain, TSC1 siRNA with apoptosis readout

   PMID:17355907

   Open questions at the time

   • Whether hamartin regulates BEX3's nuclear/transcriptional roles untested
   • Identity of the degrading E3 ligase unknown
9. 2015 High

   Revealed a nuclear, transcription-factor-like function for BEX3, demonstrating dimerization-dependent shuttling and direct association with the trkA promoter to enhance TrkA expression and neuronal survival.

   Evidence qChIP, trkA promoter reporter assays, shRNA knockdown apoptosis/differentiation readouts in sensory neurons and PC12 cells

   PMID:25948268

   Open questions at the time

   • Whether BEX3 binds DNA directly or via a cofactor not resolved
   • Other transcriptional targets not mapped
10. 2015 High

    Resolved the biophysical nature of BEX3 as an intrinsically disordered protein that nonetheless forms a defined higher-order oligomer with a folded core, reconciling its adaptor versatility with structural constraints.

    Evidence SAXS, AFM, solution NMR, CD, fluorescence, partial proteolysis of recombinant BEX3; CD/bioinformatics across the Bex family

    PMID:25612294 PMID:26383250

    Open questions at the time

    • No high-resolution structure of the oligomer
    • Disorder claim for the family rests on Bex1 CD data
11. 2017 Medium

    Extended BEX3 function to cancer by showing it regulates OCT4 expression and modulates cisplatin resistance in nasopharyngeal carcinoma.

    Evidence siRNA and shRNA knockdown with OCT4 quantification and cisplatin sensitivity assays

    PMID:28083995

    Open questions at the time

    • Mechanism linking BEX3 to OCT4 not defined
    • Single tumor type
12. 2020 Medium

    Established a physiological in vivo requirement for Bex3 in interneuron development and hippocampal circuit function.

    Evidence Two murine Bex3 alleles with interneuron histology, hippocampal electrophysiology, and behavioral testing

    PMID:33100228

    Open questions at the time

    • Molecular pathway underlying the neuronal phenotype not connected to BEX3's biochemical functions
    • Single study

• How BEX3's nuclear transcriptional activity, mitochondrial localization, apoptotic adaptor roles, and proliferation control are integrated into a single regulatory logic remains unresolved.
• No unifying model linking subcellular pools to distinct outputs
• No high-resolution structure of any BEX3 complex
• DNA-binding mechanism at the trkA promoter unknown